BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Clinical Outcome
20 results:

  • 1. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and tert promoter alterations favour malignant struma ovarii.
    Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
    Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. FOXL2 Mutation Status in Sex Cord-stromal Tumors Cannot be Predicted by Morphology.
    Wessman S; Fuentes BB; Severin-Karlsson J; Westbom-Fremer S; Nistér M; Kokaraki G; Petta TB; Haglund F; Carlson JW
    Int J Gynecol Pathol; 2024 Jan; 43(1):78-89. PubMed ID: 37255476
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
    Staubitz JI; Müller C; Heymans A; Merten C; Roos B; Poplawski A; Ludt A; Strobl S; Springer E; Schad A; Roth W; Musholt TJ; Hartmann N
    BJS Open; 2023 May; 7(3):. PubMed ID: 37146205
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genetic and epigenetic characterization of posterior pituitary tumors.
    Schmid S; Solomon DA; Perez E; Thieme A; Kleinschmidt-DeMasters BK; Giannini C; Reinhardt A; Asa SL; Mete O; Stichel D; Siewert C; Dittmayer C; Hasselblatt M; Paulus W; Nagel C; Harter PN; Schittenhelm J; Honegger J; Rushing E; Coras R; Pfister SM; Buslei R; Koch A; Perry A; Jones DTW; von Deimling A; Capper D; Lopes MB
    Acta Neuropathol; 2021 Dec; 142(6):1025-1043. PubMed ID: 34661724
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The role of the size in thyroid cancer risk stratification.
    Vianello F; Censi S; Watutantrige-Fernando S; Barollo S; Zhu YH; Albiger N; Bertazza L; Manso J; Carducci S; Benna C; Iacobone M; Galuppini F; Pennelli G; Mian C
    Sci Rep; 2021 Mar; 11(1):7303. PubMed ID: 33790328
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Spatial Distribution Patterns of clinically Relevant tert Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential: Advantages of the Digital Droplet PCR Technique.
    Hysek M; Jatta K; Hellgren LS; Stenman A; Larsson C; Zedenius J; Juhlin CC
    J Mol Diagn; 2021 Feb; 23(2):212-222. PubMed ID: 33197629
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Prognostic value of
    van Ipenburg JA; Naus NC; Dubbink HJ; van Ginderdeuren R; Missotten GS; Paridaens D; Verdijk RM
    Br J Ophthalmol; 2021 Oct; 105(10):1454-1461. PubMed ID: 33127831
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma.
    Samà MT; Grosso E; Mele C; Laurora S; Monzeglio O; Marzullo P; Boldorini R; Aluffi Valletti P; Aimaretti G; Scatolini M; Pagano L
    Endocrine; 2021 Jan; 71(1):149-157. PubMed ID: 32621051
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid cancer Cell Line.
    Hegedűs L; Rittler D; Garay T; Stockhammer P; Kovács I; Döme B; Theurer S; Hager T; Herold T; Kalbourtzis S; Bankfalvi A; Schmid KW; Führer D; Aigner C; Hegedűs B
    Pathol Oncol Res; 2020 Oct; 26(4):2523-2535. PubMed ID: 32591993
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
    Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
    Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis.
    Wong KS; Higgins SE; Marqusee E; Nehs MA; Angell T; Barletta JA
    Endocr Pathol; 2019 Mar; 30(1):43-48. PubMed ID: 30565013
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. tert promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
    Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
    Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Genetic landscape of papillary thyroid carcinoma in the Chinese population.
    Liang J; Cai W; Feng D; Teng H; Mao F; Jiang Y; Hu S; Li X; Zhang Y; Liu B; Sun ZS
    J Pathol; 2018 Feb; 244(2):215-226. PubMed ID: 29144541
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.
    Tesselaar MH; Smit JW; Nagarajah J; Netea-Maier RT; Plantinga TS
    J Mol Endocrinol; 2017 Nov; 59(4):R141-R154. PubMed ID: 28931558
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Application of molecular biology of differentiated thyroid cancer for clinical prognostication.
    Marotta V; Sciammarella C; Colao A; Faggiano A
    Endocr Relat Cancer; 2016 Nov; 23(11):R499-R515. PubMed ID: 27578827
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.
    Zheng S; Cherniack AD; Dewal N; Moffitt RA; Danilova L; Murray BA; Lerario AM; Else T; Knijnenburg TA; Ciriello G; Kim S; Assie G; Morozova O; Akbani R; Shih J; Hoadley KA; Choueiri TK; Waldmann J; Mete O; Robertson AG; Wu HT; Raphael BJ; Shao L; Meyerson M; Demeure MJ; Beuschlein F; Gill AJ; Sidhu SB; Almeida MQ; Fragoso MCBV; Cope LM; Kebebew E; Habra MA; Whitsett TG; Bussey KJ; Rainey WE; Asa SL; Bertherat J; Fassnacht M; Wheeler DA; ; Hammer GD; Giordano TJ; Verhaak RGW
    Cancer Cell; 2016 May; 29(5):723-736. PubMed ID: 27165744
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinicopathological significance of tert promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis.
    Yin DT; Yu K; Lu RQ; Li X; Xu J; Lei M; Li H; Wang Y; Liu Z
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):299-305. PubMed ID: 26732020
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Uncommon tert Promoter Mutations in Pediatric Thyroid cancer.
    Alzahrani AS; Qasem E; Murugan AK; Al-Hindi HN; AlKhafaji D; Almohanna M; Xing M; Alhomaidah D; AlSwailem M
    Thyroid; 2016 Feb; 26(2):235-41. PubMed ID: 26711586
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. tert Promoter Mutations in Papillary Thyroid Microcarcinomas.
    de Biase D; Gandolfi G; Ragazzi M; Eszlinger M; Sancisi V; Gugnoni M; Visani M; Pession A; Casadei G; Durante C; Costante G; Bruno R; Torlontano M; Paschke R; Filetti S; Piana S; Frasoldati A; Tallini G; Ciarrocchi A
    Thyroid; 2015 Sep; 25(9):1013-9. PubMed ID: 26148423
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and tert.
    Dettmer MS; Schmitt A; Steinert H; Capper D; Moch H; Komminoth P; Perren A
    Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.